Hillhouse Capital Management Ltd. grew its holdings in shares of China Biologic Products, Inc. (NASDAQ:CBPO) by 186.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 753,624 shares of the biopharmaceutical company’s stock after purchasing an additional 490,874 shares during the period. China Biologic Products comprises 1.3% of Hillhouse Capital Management Ltd.’s holdings, making the stock its 14th largest holding. Hillhouse Capital Management Ltd. owned 2.77% of China Biologic Products worth $85,235,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Oppenheimer Asset Management Inc. acquired a new position in shares of China Biologic Products during the 1st quarter worth approximately $156,000. Nomura Holdings Inc. acquired a new stake in shares of China Biologic Products in the first quarter valued at approximately $463,000. Jennison Associates LLC raised its position in shares of China Biologic Products by 0.8% in the second quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock valued at $653,000 after buying an additional 44 shares in the last quarter. AHL Partners LLP acquired a new stake in shares of China Biologic Products in the second quarter valued at approximately $842,000. Finally, First Trust Advisors LP raised its position in shares of China Biologic Products by 35.9% in the first quarter. First Trust Advisors LP now owns 11,561 shares of the biopharmaceutical company’s stock valued at $1,158,000 after buying an additional 3,053 shares in the last quarter. Hedge funds and other institutional investors own 72.82% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Hillhouse Capital Management Ltd. Acquires 490,874 Shares of China Biologic Products, Inc. (CBPO)” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another domain, it was stolen and republished in violation of United States and international copyright law. The original version of this story can be accessed at https://www.thecerbatgem.com/2017/10/04/hillhouse-capital-management-ltd-acquires-490874-shares-of-china-biologic-products-inc-cbpo.html.

Shares of China Biologic Products, Inc. (CBPO) traded up 0.80% on Wednesday, hitting $96.46. The company had a trading volume of 314,155 shares. China Biologic Products, Inc. has a 1-year low of $88.25 and a 1-year high of $126.47. The company has a 50 day moving average price of $92.58 and a 200 day moving average price of $103.50. The firm has a market capitalization of $2.63 billion, a price-to-earnings ratio of 25.11 and a beta of 1.75.

China Biologic Products (NASDAQ:CBPO) last released its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $1.35 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.30 by $0.05. The company had revenue of $89.28 million during the quarter, compared to the consensus estimate of $97.33 million. China Biologic Products had a net margin of 31.55% and a return on equity of 21.86%. China Biologic Products’s revenue for the quarter was down 2.3% on a year-over-year basis. During the same period last year, the firm earned $1.26 EPS. On average, equities analysts forecast that China Biologic Products, Inc. will post $4.96 earnings per share for the current fiscal year.

Several equities research analysts recently issued reports on the company. Jefferies Group LLC reiterated a “buy” rating and issued a $140.00 price target on shares of China Biologic Products in a research note on Monday, June 12th. BidaskClub downgraded China Biologic Products from a “hold” rating to a “sell” rating in a research report on Sunday, July 16th. Finally, Zacks Investment Research upgraded China Biologic Products from a “sell” rating to a “hold” rating in a research note on Tuesday, July 4th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $132.00.

China Biologic Products Company Profile

Want to see what other hedge funds are holding CBPO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for China Biologic Products, Inc. (NASDAQ:CBPO).

Institutional Ownership by Quarter for China Biologic Products (NASDAQ:CBPO)

Receive News & Stock Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related stocks with our FREE daily email newsletter.